September 2019 News from Champions Oncology

Covering a full range of research and development solutions that help guide decision making for clinical oncology drug development, here's where you can stay up-to-date on news, events, and special opportunities for study enrollment.

Now Enrolling
Primary AML Vitroscreen

Large-Scale In Vitro Screening Opportunity of Primary AML Models


Participate in the Champions Oncology AML VitroScreen for lower cost, large scale studies across 15 or 30 Primary AML Models.

Find out more information on the utility of this platform here.

Now Enrolling
- H
uSyngeneic Screen

Human Transgenic MC38 Syngeneic System


- C57BL/6 Mice expressing Human PD-L1 and CTLA-4
- MC38 cell line expressing human PD-L1

- Full knock-out of murine targets.
- Endogenous expression of human targets.
- The model has been characterized for Keytruda Response
- FREE Vehicle response data and 50% off Keytruda data

Learn more about this platform here.

TNBC PDX Subtyping

Champions Oncology maintains an extensive bank of hard-to-treat triple-negative breast cancer (TNBC) models. Lacking traditional surface markers such as ER and HER2, which are targeted by a number of agents, treatment options beyond standard chemotherapeutics are limited for these cancers.

However, analysis of TNBC gene expression patterns has identified specific molecular subtypes that show differential drug responses (Lehman, B.D. et al, JCI, 121(7), 2011).

Champions has now applied these in silico molecular analyses to its cohort of TNBC models, providing additional insights that may be useful for selecting appropriate models to screen experimental agents. Find out more here.

Join Us at the

2nd European Oncology and Immuno-Oncology Drug Discovery Symposium, Basel

Date: Tuesday 22nd October, 2019 9:00-17:00
Venue: Hotel Stücki, Badenstrasse 1, 4057 Basel

Learn from experts about their current therapeutic approach to today’s oncology challenges.

Gain insight on how to further support your oncology and immuno-oncology drug development programs, from preclinical and translational studies, to research in the clinic, by attending the Champions Oncology drug discovery symposium.


Free to attend, limited spaces available - sign up here

Attending ICCS in Atlanta?

Flow cytometry is becoming a critical technology to IO and oncology clinical research. 

Learn more about Champions' Clinical Flow Cytometry Services & meet our experts at booth 102.

Schedule a Meeting
Champions Oncology will be attending MetroFlow in October!  

We are excited to connect with many NYC local experts and gain insights on up-and-coming industry trends in flow cytometry.  

Stop by our table and speak with a Champions expert on our Clinical Flow Cytometry offerings.

Please contact Michelle Mack today at or
585-305-2453 for more information.

Copyright © 2019, All rights reserved.

Our mailing address is:
Corporate Headquarters
One University Plaza
Suite 307
Hackensack, NJ 07601

Champions TumorGraft is a registered trademark of Champions Oncology


Email Marketing by ActiveCampaign